News | March 06, 2014

First Patient Enrolled in Lipid-Rich Plaque Study

Testing near-infrared coronary imaging ability to predict heart attack risk

Infraredx Inc. TVC Imaging System Intravascular Ultrasound IVUS Clinical Study

March 6, 2014 — MedStar Heart Institute of Washington, D.C., and Infraredx Inc. enrolled the first participant in the Lipid-Rich Plaque (LRP) Study. The LRP Study is a prospective, multi-center study aimed at identifying a correlation between LRPs and the occurrence of a cardiac event within two years. LRPs, which are implicated in most heart attacks, will be identified in study participants using the Infraredx TVC Imaging System, a dual modality intravascular imaging catheter.

MedStar Heart Institute is one of the 100 clinical sites worldwide to participate in the trial. 

“We are pleased to announce the start of enrollment for this major international study testing the ability of near-infrared spectroscopy (NIRS) to detect the cholesterol-rich plaques suspected of causing heart attacks,” said James Muller, M.D., co-founder and chief medical officer of Infraredx. “The decision to undertake this important study was based on a wealth of data stemming from decades of research and development by a dedicated team of more than 100 engineers and clinical scientists. Once completed, the LRP Study could redefine the role of intravascular imaging and lay the groundwork for changing standard protocol for managing coronary artery disease.”

The TVC Imaging System integrates NIRS to detect lipid-core plaques, and enhanced intravascular ultrasound (IVUS) to visualize the vessel structure, including the presence of plaques and the degree of stenosis. The system identifies plaques suspected to be vulnerable to rupture, which can cause a fatal coronary blockage. Current methods of diagnosing coronary artery disease are limited in their ability to detect such plaques.

Previous studies have demonstrated that NIRS imaging in patients can identify cholesterol-rich plaques that have caused a heart attack or cardiac arrest. In a heart attack study published in the Journal of the American College of Cardiology Cardiovascular Interventions, researchers used NIRS imaging to detect a lipid-rich plaque at the culprit site in 19 of the 20 patients studied. This data was featured as one of Discover magazine’s top 100 science stories of 2013.

“The LRP Study could be the largest study to use intravascular imaging to link suspected vulnerable plaques to a higher risk of future coronary events.” said Ron Waksman, M.D., international principal investigator of the LRP Study, and director of cardiovascular research and advanced education at the MedStar Heart Institute. “Successful identification of vulnerable plaques could help clinicians better manage high-risk patients and potentially prevent coronary events with the vast array of currently available interventional devices.”

For more information: clinicaltrials.gov

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
Overlay Init